197 related articles for article (PubMed ID: 35483417)
1. The paradox of Myeloid Leukemia associated with Down syndrome.
Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
3. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
4. Leukemogenesis in infants and young children with trisomy 21.
Roberts I
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):1-8. PubMed ID: 36485097
[TBL] [Abstract][Full Text] [Related]
5. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
6. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
7. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
8. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
[TBL] [Abstract][Full Text] [Related]
10. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS).
Al-Kershi S; Golnik R; Flasinski M; Waack K; Rasche M; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
Klin Padiatr; 2021 Nov; 233(6):267-277. PubMed ID: 34407551
[TBL] [Abstract][Full Text] [Related]
12. Management of Down Syndrome-Associated Leukemias: A Review.
Verma A; Lupo PJ; Shah NN; Hitzler J; Rabin KR
JAMA Oncol; 2023 Sep; 9(9):1283-1290. PubMed ID: 37440251
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome for Down syndrome patients with hematopoietic disorders.
Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
[TBL] [Abstract][Full Text] [Related]
14. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
15. Transient abnormal myelopoiesis in non-Down syndrome neonate.
Ohkawa T; Miyamoto S; Sugie M; Tomizawa D; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
Pediatr Int; 2015; 57(1):e14-7. PubMed ID: 25711269
[TBL] [Abstract][Full Text] [Related]
16. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
[TBL] [Abstract][Full Text] [Related]
17. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
18. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
19. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
[TBL] [Abstract][Full Text] [Related]
20. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions.
van den Akker TA; Liu YC; Liu H; Chapman J; Levine JM; Weinberg OK; Geyer JT
Pathobiology; 2024; 91(1):89-98. PubMed ID: 36996802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
